Background: Postherpetic neuralgia (PHN) is a nerve pain disease usually controlled by different therapies, i.e., topical therapies, antiepileptics, analgesics, antipsychotics, antidepressants, anti-dementia drugs, antivirals, amitriptyline, fluphenazine, and magnesium sulfate. It is believed that different therapies may lead to different levels of pain relief.
P P
ostherpetic neuralgia (PHN) is a common type of neuropathic pain syndrome, characterized as pain persisting for at least 120 days at the site of acute herpes zoster subsequent to rash onset (1) . It has been reported that approximately 10 -20% of patients with herpes zoster will develop PHN, and there is a positive correlation between the severity/ www.painphysicianjournal.com searched in China National Knowledge Infrastructure (CNKI), PubMed, and Embase using the following terms along with their synonyms: "post-herpetic neuralgia," "topical therapies," "antiepileptics," "analgesics," "opioid," "antipsychotics," "antidepressants," "anti-dementia drugs," "antivirals," "amitriptyline and fluphenazine," "magnesium sulfate," and "randomized controlled study." Additional articles from other sources, such as previous meta-analyses, were added for screening to enhance the comprehensiveness of the systematic review.
Literature Screening and Inclusion
To ensure the validity and accuracy of the systematic review, the titles and abstracts of all of the identified articles were inspected and screened independently by 2 experts, and consensus was reached through discussion when any disagreement emerged. Only those fulfilling the following criteria were included in the systematic review: 1) Studies conducted as randomized controlled trials (RCTs).
2) The data for PHN treatments could be extracted. 3) Comparison among at least 2 treatments mentioned above (placebo included) was conducted. 4) At least one pain scale from baseline to endpoint was given.
Data Extraction
Full texts of the qualified articles were accessed, and data extraction was conducted by 2 authors independently. The extracted data included the name of author, publication year, study design, follow-up period, treatment class, specific treatment, number of cases, mean age, female to male ratio, and pain scale. Any disagreement was resolved through discussion.
Data Analysis
A pain scale was the only parameter that measured the efficacy of each treatment. However, different types of pain scales were used in different included studies. Thus, we used the standardized mean difference (SMD) of pain scale changes from baseline to endpoint between each intervention group to address this issue. The results were expressed as SMD with 95% confidence intervals (CIs) for direct comparisons and credible intervals (CrIs) for indirect comparisons. A negative SMD value suggested that one treatment is potentially more efficacious than another with respect to pain relief.
In the systematic review, a traditional pairwise meta-analysis was firstly performed to determine the There are 2 groups of therapies usually prescribed for PHN patients: topical therapies (lidocaine and capsaicin) and systemic therapies (7) . Topical agents, such as l idocaine, are formulated to provide patients with local pain relief while minimizing systemic absorption (8) . In addition, NGX-4010, a high-concentration capsaicin (8%), is reported to relieve pain for up to 12 weeks in PHN patients (9) . Systemic therapies include a ntiepileptics, analgesics, antipsychotics, antidepressants, anti-dementia drugs, and magnesium sulfate (7) . In addition, the varicella zoster virus vaccine was able to reduce the incidence of herpes zoster as well as PHN, indicating that antivirals may be effective for PHN patients (10) . A combination therapy of amitriptyline and fluphenazine (A&F) also showed its efficacy for PHN patients (11) . However, relative efficacy of these therapies remains unclear (12) . As a result, evaluation and comparison for these potential therapies with respect to efficacy is essential in clinical practice.
A variety of previous studies have assessed the efficacy of PHN treatments. However, the majority of these studies were trials or reviews, which only provided direct comparisons (13, 14) . Apart from that, the power of some studies was limited by a small sample size, which may provide insignificant conclusions (15, 16) . Furthermore, there is no consensus with respect to the selection of an appropriate PHN therapy. For instance, some literatures recommended topical lidocaine as a first-line agent for PHN treatment (17, 18) , while others denied such a recommendation due to inadequate evidence (19) . Another limitation in the current literature is that the efficacy of PHN therapies was assessed using a wide range of criteria. The adoption of different criteria reduced the level of evidence consistency and caused potential contradiction.
Network meta-analysis (NMA) combines both direct and indirect evidence based on clinical trials. Nowadays, it is believed to be of high-reference-value for intervention superiority evaluation. For this sake, we designed and implemented this NMA which compared the efficacy of 9 popular PHN therapies (topical agents, antiepileptics, analgesics, antipsychotics, antidepressants, anti-dementia drugs, antivirals, A&F, and magnesium sulfate) and came up with the optimal choice for future clinical practice.
M ETHODS

Literature Search Strategy
Relevant studies published before August 2016, regardless of the publication date and language, were Pain Relief in PHN Therapies relative efficacy of the different treatments for PHN. Indirect comparisons among multiple treatments were conducted by using the approach of a NMA. All statistical analyses were conducted using R version 3.2.3 (The R Foundation for Statistical Computing), and the Bayesian framework was adopted for the implementation of NMA. The ranking probability of each treatment was produced by the surface under the cumulative ranking curve (SUCRA), which was established as a ranking scheme for the treatments.
Moreover, the Cochran's Q-statistic and I 2 test were evaluated to examine the heterogeneity among the selected studies, where P < 0.01 or I 2 > 50% indicated the existence of significant heterogeneity, in which the fixed-effects model (Mantel-Haenszel method) was replaced by the random-effects model (DerSimonian-Laird method). Inconsistencies between direct and indirect evidence were also assessed on the basis of the nodesplitting method and were visualized using a net heat plot. In addition, publication bias was investigated and assessed using the funnel plot.
RESULTS
Study Characteristics
As shown in Fig. 1 , the identification, screening, and inclusion process of eligible studies is illustrated in a flowchart. Initially, 720 records were identified through initial searching in CNKI, PubMed, and Embase along with an additional 36 records added through other sources, such as references from selected meta-analyses and ClinicalTrials.gov. After removing duplicates and irrelevant articles, 321 studies remained for further inspection. Consequently, 246 records were excluded due to incomplete data or other reasons, leaving 75 records which were subject to full-text review. During data extraction, several records without sufficient data or proper comparisons that could form a network were www.painphysicianjournal.com further removed. As a result, 27 records were included in this systematic review. The baseline characteristics of each enrolled study are summarized in Table 1 (9, 11, (13) (14) (15) (16) . In the 27 records, 9 classes of drugs (placebo Abbreviations: A&F = amitriptyline and fluphenazine; TCA = tricyclic antidepressants; PRI = pain rating index; NPRS = numeric pain rating scale; VAS = visual analog scale for pain; NPS = neuropathic pain scale; NRS = numeric rating scale; PI-NRS = pain intensity numerical rating scale; PPI = present pain intensity score; NPSI = neuropathic pain symptom inventory; ADP = average daily pain score; DPRS = daily pain rating scale; -= not specified not included) were involved: topical therapies, antiepileptics, analgesics, antipsychotics, antidepressants, antidementia drugs, antivirals, A&F, and magnesium sulfate. As illustrated in Fig. 2 , the corresponding direct and indirect comparisons are presented in the network plot.
Risk of Publication Bias
The effect of study sizes versus standard errors was investigated via funnel plots. Typically, publication bias, which implies differences among different study sizes, is reported to show if an asymmetrical funnel plot occurs. As shown in Fig. S1 , the funnel plot pattern in the systematic review exhibited no significant asymmetry pattern, indicating a low risk of publication bias.
P airwise Comparison
As shown in Table 2 , a total of 15 groups of traditional pairwise comparison were conducted, in which SMD, 95% CIs, and P-value of each comparison were calculated and presented. In contrast to placebo, 4 treatment classes, including t opical therapies (SMD = -0. 
NMA
Results of the NMA are displayed in Table 3 and 
Consistency Assessment
This systematic review was based on a consistency model, the validity of which could be compromised by significant inconsistency between direct and indirect www.painphysicianjournal.com evidence. The node-splitting method (41) was employed to assess the degree of consistency in the systematic review, where P < 0.01 implied significant inconsistency. The results are shown in Table S1 , suggesting that there was no significant inconsistency between direct and indirect evidence in the systematic review. Additionally, a net heat plot was drawn in Fig. S2 (42) . Similarly, no significant inconsistency between direct and indirect comparisons was observed.
Ranking of Treatment Classes
As shown in Fig. 4 , the rank probabilities of each treatment class were calculated and cumulative probability rank curves were plotted. The mean rank and SUCRA of each treatment were also calculated and are presented in Table S2 . A nalgesics and magnesium sulfate ranked first and second concerning pain relief, respectively and were considered to be optimal candidates for PHN treatment with SUCRAs over 0.70. The secondary favorable treatments were antiepileptics and antidepressants, both of which had a SUCRA value around 0.60. In contrast, antivirals appeared to be the least favorable treatment due to having the lowest SUCRA values.
DISCUSSION
In this NMA, we focused on the comparable efficacy of 9 classes of PHN therapies. In view of pain relief or pain intensity measured using different scales (pain rating index [PRI] , numeric pain rating scale [NPRS], visual analog scale [VAS]) in the included studies, we evaluated the mean changes on pain intensity before and after the treatments and compared the pain relief effects using the statistics of SMD. In this NMA, both direct and indirect evidence demonstrated that analgesics, antidepressants, antiepileptics, and topical therapies were significantly preferable than placebo with respect to pain relief, which is consistent to the recommendation of previous guidelines (43) . As for the overall rank, it was suggested by our SUCRA results that analgesics and magnesium sulfate exhibited the best efficacy with respect to PHN pain relief, whereas antivirals appeared to be the least effective class of therapy.
Consistent to our results, the pain relief effect of analgesics and magnesium sulfate have been found and verified for years in several neuropathic pains, such as migraine pain, phantom limb pain, and nerve injury pain (44) (45) (46) . The underlying mechanisms linking these 2 therapies to PHN pain relief may be associated Pain Relief in PHN Therapies with the N-methyl-D-aspartate (NMDA) receptor. The NMDA receptor, which is reported to be involved in the control of PHN, is of great importance to the development of central sensitization, neuroplasticity changes, and expansion of receptive fields in the central nervous system (47) (48) (49) . Both ketamine (a type of analgesics) and magnesium sulfate are NMDA antagonists, and by blocking the phencyclidine site and calcium channels of the NMDA receptor, respectively, these 2 therapies can arrest the neural activity mentioned above, thus suppressing neuropathic pain (47, 50) .
However, the direct evidence for magnesium sulfate was based on only one study with 15 cases, which may make the results biased. This limitation also existed in the evaluation of some other effective therapies in this systematic review, including analgesics and antidepressants. For this reason, we noticed another class of PHN therapy, antiepileptics, which was well-supported by sufficient evidence in this systematic review and exhibited its efficacy on pain relief.
Numerous studies have focused on the pain relief effect of antiepileptics for patients with PHN. For instance, gabapentinoid antiepileptic drugs have exhibited prominent efficacy on reducing PHN pain in a variety of clinical trials (28, 35) and were recommended as the first-line treatments for PHN (51) . The pharmacological mechanism lies in that gabapentinoid drugs can inhibit calcium currents by high-voltage-activated channels, contributing to the reduction of neurotransmitter release and attenuation of postsynaptic excitability. However, carisbamate, a novel antiepileptic, did not outperform placebo in a study included in our NMA (14) , suggesting that not all of the antiepileptics for PHN pain relief were effective.
Additionally, the efficacy of antivirals ranked the lowest and even less effective than placebo. Antiviral agents are not the treatments for PHN pain relief, but are interventions for PHN prevention (52) . Besides that, there is only one direct comparison containing antivirals in this systematic review, and only one kind of antiviral agent was assessed (15) . Moreover, acyclovir, the only antiviral agent evaluated in this systematic review, has been confirmed ineffective in reducing the incidence of PHN in previous literatures (52, 53) . However, evidence for other new antiviral agents was hard to find, and therefore the effect of antivirals on PHN prevention or pain relief is still in need of future investigations.
There are several limitations of this systematic review. Firstly, as mentioned above, there is a lack of direct head-to-head comparisons of some treatments, especially for antivirals, anti-dementia drugs, and magnesium sulfate. Though this limitation was addressed by the method of NMA to a certain extent, more direct evidence is still needed to draw more robust and reliable conclusions. Secondly, the specific agents belonging to a same class of therapies might exhibit different effects (gabapentin and carisbamate) w ith different mechanisms (opioids and ketamine) on reducing pain, and some agents were hard to find in literatures and were not involved in the systematic review, which may influence our results and contribute to the heterogeneity. In addition, some confounding factors which were inherent in the studies we included, such as the age of patients and the dose of agents, can also affect the results of this systematic review. Moreover, this NMA only focused on the pain relief effect of these treatments and did not assess the adverse events. Therefore, more well-designed studies, which take these confounding factors into consideration and measure the adverse events, are needed to improve the analysis.
In conclusion, both of the NMDA receptor antagonists, analgesics and magnesium sulfate, were preferable to the other treatments with respect to pain relief for PHN, although further evidence were required to confirm their clinical performance, while antivirals was the least effective class and even worse than placebo and should be ruled out when carrying out clinical practice based on our analysis.
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Abbreviations: SUCRA, surface under the cumulative ranking; A&F, amitriptyline and fluphenazine. a The treatments are sorted in descending order of SUCRA.
